NCI-H209細(xì)胞

細(xì)胞形態(tài)： 上皮樣

ATCC Number： HTB-172?

相關(guān)**： 小細(xì)胞肺癌

生長狀態(tài)： 懸浮生長

是否是腫瘤細(xì)胞： 1

物種來源： 人

運(yùn)輸方式： 凍存運(yùn)輸

數(shù)量： 大量

器官來源： 肺

Designations: NCI-H209 [H209]

Depositors: AF Gazdar, JD Minna

NCI-H209細(xì)胞Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: aggregates in suspension

Organism: Homo sapiens

Morphology: epithelial

Source: Organ: lung

Disease: carcinoma; small cell lung cancer

Derived from metastatic site: bone marrow

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Tumorigenic: Yes

Oncogene: pRB + (abnormal, RB1)

DNA Profile (STR): Amelogenin: X,Y

CSF1PO: 11

D13S317: 11

D16S539: 9,12

NCI-H209細(xì)胞D5S818: 12

D7S820: 9

THO1: 7,9

TPOX: 8

vWA: 18,19

Cytogenetic Analysis: This is a hyperdiploid human cell line., The modal chromosome number is 49, occurring at 28% with a frequency of higher ploidies of 1.3%. Ten to eleven markers were common to all cells including: der(1)t(1;3)(p22;p21), del(6)(q21), t(8q18q), del(12)(q13), der(14)t(14;?)(q32;?)., All had a single copy per cell. About 6 other markers were found, but they occurred only once in all metaphases karyotyped. Neither HSR nor DM were detected., Structurally normal B group chromosomes were not detected. All C group chromosomes were paired. A single copy of both the X and Y was found in all cells.

Isoenzymes: AK-1, 1

ES-D, 1

G6PD, B

Me-2, 0

PGM1, 1-2

PGM3, 1

Gender: male

Ethnicity: Caucasian

Comments: NCI-H209細(xì)胞The NCI-H209 cell line was derived by A.F. Gazdar and associates in 1979 from the bone marrow of a patient with small cell cancer of the lung.

The bone marrow specimen was taken prior to therapy.

The line is a classic SCLC cell line which expresses elevated levels of four biochemical markers (neuron specific enolase, brain isoenzyme of creatine kinase, L-DOPA decarboxylase and bombesin-like immunoreactivity.

C-myc DNA sequences are not amplified.

No gross structural DNA abnormalities were detected.

The line produces normal amounts of p53 mRNA relative to normal lung.

This is a cell line that grows as large aggregates in suspension. Only the aggregates are viable, but no meaningful viability percentage can be measured. The medium will normally contain large amounts of cell debris.

The cells express an aberrant form of RB1 that is not phosphorylated, apparently due to a single point mutation at codon 706 (Cys -> Phe).

Propagation: ATCC complete growth medium: Iscove's modified Dulbecco's medium, 90%; fetal bovine serum, 10% - OR - RPMI 1640 medium, 90%; fetal bovine serum, 10%

Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended

Medium Renewal: NCI-H209細(xì)胞2 to 3 times per week

The line should be subcultured by dilution with fresh medium. Alternatively, the clusters may be collected by centrifugation and resuspended in fresh medium.

Preservation: Culture medium, 95%; DMSO, 5%

Related Products: normal (or near-normal) cell line established from the same patient:ATCC CRL-5948

References: 1805: Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201

1806: Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494

23056: Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257

23080: Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370

23320: Kaye FJ, et al. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc. Natl. Acad. Sci. USA 87: 6922-6926, 1990. PubMed: 2168563

32276: Cairns P, et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. PubMed: 9393760

32287: Rostomily RC, et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997. PubMed: 9270024